About The Gazette Search Back Issues Contact Us    
The newspaper of The Johns Hopkins University September 11, 2006 | Vol. 36 No. 2
Closing In On Lethal Heart Rhythm in Young Athletes

New findings at Johns Hopkins should improve screening and prevention

By David March
Johns Hopkins Medicine

Johns Hopkins experts on the genetics of a potentially lethal heart rhythm defect that runs in families and targets young athletes report they have greatly narrowed the hunt for the specific genetic mutations that contribute to the problem.

Their new findings, described in the July issue of the American Journal of Human Genetics, should increase the accuracy of tests to identify those at risk for arrhythmogenic right ventricular dysplasia, known as ARVD, which is among the top causes of sudden cardiac death in the young and fit.

In February, the same team linked one-third of ARVD cases in their large database of patients to a dozen abnormal changes in a gene called plakophilin 2, which makes proteins involved in heart cell stickiness.

In the new study, confirming experiments elsewhere, the Hopkins team found four mutations in another sticky protein gene, Desmoglein 2, in five of 33 patients tested.

"This gene is highly expressed in the heart, where muscle tissue expands and contracts with the heartbeat," said senior study author and cardiac geneticist Daniel P. Judge. "Our results confirm that altered genes in the desmosomal cellular complex are responsible for ARVD. And now that we know the genetic roots of this disease, we can also create better blood tests for their proteins to predict who is at risk for developing this condition."

ARVD is characterized by weakness in the desmosome, or cell-to-cell binding structure. The inherited condition leads to the buildup of excess fatty and scar tissue in the heart's right ventricle, causing irregular beats and — unless diagnosed and treated with drugs or implanted defibrillators — triggering a fatal heart rhythm disturbance.

Judge, an assistant professor at the School of Medicine and its Heart Institute, says DSG2 mutations appear to account for at least 10 percent and possibly more of the estimated 25,000 deaths each year from ARVD.

The researchers, he said, expect a test for DSG2 mutations to be available to those with a family history of the condition before the end of the year.

The same Hopkins team developed a blood test to screen for PKP2 mutations. That test became available in May and is currently the only one available for detecting those at greater risk of the disease.

More than 400 people have been screened at Johns Hopkins so far and, of these, two-thirds have had serious enough forms of the condition to warrant implantation of a defibrillator, an electrical device that corrects any disturbances in the heart's rhythm.

The Hopkins researchers identified the DSG2 mutation through genetic analysis of blood taken from 60 men and women already diagnosed with ARVD. All were part of a patient database created at Hopkins in 1998. The researchers focused on cell adhesion proteins because they had already been linked to Naxos syndrome, which produced symptoms in the right ventricle similar to those documented in ARVD.

When scientists excluded their ARVD patients with PKP2 mutations, they were left with 33 who had no known genetic explanation for their condition. Additional testing revealed the four mutations in DSG2.

"We knew right away that we had found something very significant," said lead author Mark Awad, a medical and predoctoral sciences student at Hopkins. "The mutations were confined to a highly functional part of the gene and were highly conserved, meaning that evolution had not drastically changed the genetic sequence over time — the gene was kept the way it was because it was important to the heart's normal function."

According to Awad, not everyone with a genetic mutation develops ARVD. Further analysis of the condition's genetic roots, he said, will help researchers to calculate the precise increased risk from each mutation for developing symptoms and dying. Previous research by the Hopkins team showed that familial ARVD generally strikes after puberty and its symptoms — dizziness, fatigue and fainting after exercise — may appear up to 15 years before diagnosis.

Funding for this study was provided by the Bogle Foundation, Campanella family, Wilmerding Endowments, National Institutes of Health, Donald W. Reynolds Foundation and W.W. Smith Charitable Trust.

In addition to Judge and Awad, other researchers involved in this study, conducted solely at Hopkins, were Darshan Dalal, Eunpi Cho, Nuria Amat Alarcon, Cynthia James, Crystal Tichnell, April Tucker, Stuart Russell, David Bluemke, Harry Dietz and Hugh Calkins. Calkins receives research support from device manufacturers Guidant, Medtronic and St. Jude. The terms of these arrangements are being managed by The Johns Hopkins University in accordance with its conflict-of-interest policies.


Related Web site

ARVD program at Johns Hopkins


The Gazette | The Johns Hopkins University | Suite 540 | 901 S. Bond St. | Baltimore, MD 21231 | 443-287-9900 |